Improving prescription drug quality is an essential health policy goal in modern health systems, though evidence on the available instruments to attain such a goal are scarce. Cost sharing has an arguable role in improving the likelihood of an individual obtaining an appropriate prescription....

The persistence of socioeconomic inequalities in health is a major policy concern in England, which was addressed by the new labour government in 1997 which prioritised curtailing health inequalities as a policy goal. This paper addresses two related questions: first, it empirically examines the...

Both public and private insurance for long-term care (LTC) in European countries employed is underdeveloped. However, limited evidence is gathered on the behavioural demand responses to the introduction of insurance schemes expanding insurance coverage. This paper aims at empirically examining...

The sluggish development of European generic drug markets depends heavily on demand side factors, and more specifically, patients’ and doctors’ loyalty to branded products. Loyalty to originator drugs, to the point where originator prices rise upon generic entry has been described as the...

There is a widely discussed problem of publication bias in medical and health services research. Where quantitative effects form the basis of a publication a ‘winner's curse’ curse may apply. This phenomenon may occur as prospective authors of research papers compete by reporting ‘more...

We argue that policy analysis aiming at curving inequalities in health calls for a better understanding of what we know about its measurement pathways. Assuming that health is a good that individuals trade off against other goods, unavoidable health inequalities result when after controlling for...